Assignee
LOXO ONCOLOGY INC
US·33 granted patents·11 pending applications·81 citations·filing 2015–2025
Top patents by PatentIndex Score
44 records- 0194US10137127B2Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamideLOXO ONCOLOGY INC·Filed 2017·Granted Nov 27, 2018·17 cites·30 claims
- 0293US10045991B2Methods of treating pediatric cancersLOXO ONCOLOGY INC·Filed 2017·Granted Aug 14, 2018·11 cites·27 claims
- 0391US10907215B2Point mutations in TRK inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2018·Granted Feb 2, 2021·3 cites·27 claims
- 0491US10786489B2Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2018·Granted Sep 29, 2020·9 cites·18 claims
- 0590US10724102B2Point mutations in TRK inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2016·Granted Jul 28, 2020·3 cites·44 claims
- 0690US10655186B2Point mutations in TRK inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2017·Granted May 19, 2020·3 cites·14 claims
- 0789US2025090500A1Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 0888US10668072B2Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamideLOXO ONCOLOGY INC·Filed 2018·Granted Jun 2, 2020·2 cites·22 claims
- 0988US10342780B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2018·Granted Jul 9, 2019·2 cites·24 claims
- 1088US9975897B2Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinaseLOXO ONCOLOGY INC·Filed 2015·Granted May 22, 2018·11 cites·21 claims
- 1187US12220401B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2023·Granted Feb 11, 2025·0 cites·6 claims
- 1287US11471441B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2020·Granted Oct 18, 2022·1 cites·10 claims
- 1387US10588908B2Methods of treating pediatric cancersLOXO ONCOLOGY INC·Filed 2018·Granted Mar 17, 2020·3 cites·28 claims
- 1485US10695323B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2016·Granted Jun 30, 2020·2 cites·35 claims
- 1585US10378068B2Point mutations in TRK inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2017·Granted Aug 13, 2019·3 cites·20 claims
- 1685US10370727B2Point mutations in TRK inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2017·Granted Aug 6, 2019·3 cites·20 claims
- 1784US10918622B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2020·Granted Feb 16, 2021·1 cites·14 claims
- 1884US10745419B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2018·Granted Aug 18, 2020·2 cites·19 claims
- 1983US10464905B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2018·Granted Nov 5, 2019·1 cites·29 claims
- 2081US11191766B2Methods of treating pediatric cancersLOXO ONCOLOGY INC·Filed 2020·Granted Dec 7, 2021·1 cites·22 claims
- 2181US11098064B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrileLOXO ONCOLOGY INC·Filed 2020·Granted Aug 24, 2021·1 cites·9 claims
- 2280US11826351B2Compounds useful as kinase inhibitorsLOXO ONCOLOGY INC·Filed 2021·Granted Nov 28, 2023·0 cites·27 claims
- 2378US12268666B2Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamideLOXO ONCOLOGY INC·Filed 2024·Granted Apr 8, 2025·0 cites·8 claims
- 2478US12138250B2Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2022·Granted Nov 12, 2024·0 cites·13 claims
- 2577US11963950B2Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2021·Granted Apr 23, 2024·0 cites·23 claims
- 2677US10538524B2Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinaseLOXO ONCOLOGY INC·Filed 2018·Granted Jan 21, 2020·2 cites·18 claims
- 2775US2021164055A1Point mutations in trk inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 2871US12102621B2Formulations of 6-(2-hydroxy-methylpropoxy-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2020·Granted Oct 1, 2024·0 cites·16 claims
- 2969US11807651B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2021·Granted Nov 7, 2023·0 cites·11 claims
- 3069US10399989B2Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancerLOXO ONCOLOGY INC·Filed 2018·Granted Sep 3, 2019·0 cites·24 claims
- 3168US11484535B2Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamideLOXO ONCOLOGY INC·Filed 2020·Granted Nov 1, 2022·0 cites·33 claims
- 3264US2025186400A1Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamideLOXO ONCOLOGY INC·Filed 2025·Application pending·0 cites
- 3362US12109193B2Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamideLOXO ONCOLOGY INC·Filed 2019·Granted Oct 8, 2024·0 cites·6 claims
- 3461US2024207229A1Cocrystalline forms of a bruton's tyrosine kinase inhibitorLOXO ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 3560US10399990B2Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancerLOXO ONCOLOGY INC·Filed 2018·Granted Sep 3, 2019·0 cites·30 claims
- 3660US2022088021A1Methods of diagnosing and treating cancerLOXO ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 3757US10611766B2Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancerLOXO ONCOLOGY INC·Filed 2016·Granted Apr 7, 2020·0 cites·18 claims
- 3853US2023212193A1Crystalline ret inhibitorLOXO ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 3953US2023183266A1Crystalline forms of ret inhibitor and preparation thereofLOXO ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 4052US12551463B2Dosing of a Bruton's tyrosine kinase inhibitorLOXO ONCOLOGY INC·Filed 2020·Granted Feb 17, 2026·0 cites·8 claims
- 4150US2023322682A1Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1h-pyrazole-4-carboxamideLOXO ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 4250US2023321098A1Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancersLOXO ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 4345US2018140604A1Methods of diagnosing and treating cancerLOXO ONCOLOGY INC·Filed 2016·Application pending·0 cites
- 4442US2021023086A1Treatment of trk-associated cancersLOXO ONCOLOGY INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LOXO ONCOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →